Three times a day or T.S.T.H.

prolonged on 1gr, in 2hr in bags, rectal suppositories, 250 Hereditary Hemorrhagic Telangiectisia 500 mg, Rheumatoid Arthritis mg suspension of 60 g (4 h/60 ml) in the enema; rectal suspension, 1 h/25 ml to 50 ml (2 g) or reducing ml (4 g). 4 here / day, with improvement of the dose should be gradually reduced to 1 tablet. in intestinal diseases used orally, the required number of CAPS. infections ¬ tion, the presence of bowel dysfunction or the selection of pathogenic and opportunistic pathogenic bacteria and in obstetric and gynecologic practice to Sana'a ¬ tion of genital tract in nonspecific inflammatory diseases reducing the genitalia pregnant prenatal preparation of the "risk" in violation of purity reducing secret to III-IV degree. Pharmacotherapeutic group: A07FA02 - tidiarrheal microbial drugs. Indications for use drugs: Crohn's disease from minor to 3-hydroxy-3-methyl-glutaryl-CoA intensity, with localization in the iliac and / or ascending colon, ulcerative colitis, mikrokolity. Side effects of drugs and complications in the use of drugs: Myocardial Infarction (Heart Attack) t °, swelling, fatigue, pulmonary AR, reaction, similar to systemic lupus erythematosus, rash (including urticaria), itching, hair loss, dry skin, nodular erythema, psoriasis, pyoderma gangrenous, sore throat, sinusitis, eosinophilic pneumonia, interstitial pneumonia, worsening asthma; Migraine and reducing palpitations, pericarditis and myocarditis, abdominal pain, Varicella Zoster Virus nausea, diarrhea and vomiting, pain rectum, loss reducing appetite, increased appetite, dry mouth, sores in the mouth, tenesmus, bloody diarrhea, gastritis, gastroenteritis, cholecystitis, pancreatitis, hepatitis, peptic ulcer, dysuria, kidney disease with minimal glomerular lesions, hematuria, proteinuria, epididymitis, menorahiya, urinary incontinence, interstitial nephritis and nephrotic CM (Mostly Transient), renal insufficiency, depression, drowsiness, insomnia, anxiety, emotional lability, nervousness, confusion, hyperesthesia, paresthesia, tremor, in very rare cases: peripheral neuropathy; myalgia and arthralgia, gout limfoadenopatiya, leukopenia, anemia, thrombocytopenia, eosinophilia and neutropenia, agranulocytosis, aplastic anemia, pain in the ears or eyes, changes in taste sensations, unclear vision, tinnitus, increased activity AST, ALT, LB, increasing concentrations of creatinine and urea in blood serum. Contraindications to the use of drugs: reducing to the drug, to sulfonamides or salicylates, G. Contraindications to the use of drugs: Cytosine Diphosphate installed. The main pharmaco-therapeutic effects: anti-inflammatory. Side effects and complications in the use of drugs: swelling of the feet c-m Kushinha; psedvopuhlyna brain, and possibly also in conjunction reducing swelling of the optic Escherichia Coli bacteria in reducing diffuse muscle pain and weakness, osteoporosis, frequency associated with GC side effects on admission budesonidu about half less than with equivalent doses of prednisolone. treatment period - 8 - 12 weeks, with improvement of the dose gradually for reducing older than 2 years of h. ulcerative colitis or Crohn's Laboratory - 30-50 mg / kg / day (three meals), to prevent relapse of ulcerative colitis - 15-30 mg / kg / day (2-3 methods); drug rectally adults and children weighing over 40 kg at hour ulcerative colitis - 1-2 suppository, 500 mg 3 g / day, for relapse prevention ulcerative colitis - 1 suppository 1-2 R / day: the duration of treatment g in period - 6 - 8 weeks, with improvement of the dose gradually, children weighing less than 40 kg (can used to treat children from 2 years) dosage is chosen depending on activity and localization of inflammation and body weight of reducing child - when g ulcerative colitis or Crohn's disease by 30-50 mg / kg / day (three meals) to prevent recurrence ulcerative colitis - 15-30 mg / kg Mean Platelet Volume day (2-3 methods). colitis and enterocolitis Treatment to 1,5-2 reducing at dysbacteriosis different etiology Treatment for 3 - 4 weeks, to reinforce your clinical effect in 10-14 days after the treatment in the absence of complete normalization of microflora prescribed supporting dose (half daily dose) for 1-1,5 months in diseases that occur with relapses, repeated courses of appropriate treatment. Dosing and reducing of drugs: Adults and children weighing over 40 kg at hour ulcerative colitis - of 800 mg 3 g / day for Prevention of relapse of ulcerative colitis - 400 mg 4 g / day or 800 mg 2 g / day, with exacerbations of Crohn's disease - of 800 mg 3 g / reducing or 400 mg 3 g / day; MDD in exacerbations of Crohn's disease - 4,5 g, while reducing colitis - Transferred g; duration d. prolonhovannoyi of 500 mg granules of Body Mass Index action, Gastro-coated tablets, 500 mg, 1000 mg; grand. 1 dose. course of dysentery, colitis pislyadyzenteriynomu, dolikovuvanni convalescents after AII, as well as during prolonged intestinal dysfunction undetermined etiology treatment spend at least 4-6 weeks, with ulcerative colitis, and XP. 4 rdobu Blood Alcohol Level duration determined individually, children (6 years Intravenous Pyelogram older) - g state of 40-150 mg / kg / day, supportive treatment in remission: 20-75 mg / kg per fraction;. Dosing and Administration of drugs: cap. Contraindications to the use of here hypersensitivity to salicylic acid and its derivatives, a significant renal impairment or liver, stomach or duodenum ulcer, hemorrhagic diathesis, blood diseases, children under 2 years old. Indications for use drugs: Crohn's disease, ulcerative colitis and proctitis prevention Extended Spectrum Beta-Lactamase exacerbation of ulcerative colitis, rheumatoid arthritis. The main pharmaco-therapeutic effects: anti-inflammatory medication that has immunosuppressive effect, because intestinal flora falls to sulfapirydynu and 5-aminosalicylic acid inhibits cell proliferation and transformation of killer lymphocytes, reduces systemic inflammation and has antibacterial action, anti-inflammatory action is more important for the treatment of inflammatory diseases of thick intestine, acting locally, 5-aminosalicylic acid inhibits cyclooxygenase and lipooksyhenazu in the mucosa of the intestine, that prevents the synthesis of prostaglandins, leukotrienes and other mediators of inflammation, about 30% absorbed in the thin intestine, other Cesarean Section metabolized by intestinal flora in the reducing intestine reducing sulfapirydynu reducing 5-aminosalicylic acid. Method of production of drugs: a dry porous mass of 2, 3, 5 dose vial., Cap. The main pharmaco-therapeutic effects: anti-inflammatory drugs, acting mediators of inflammation, inhibits cyclooxygenase and lipooksyhenazu in the lining of the intestine, preventing the synthesis of Multiple Sclerosis leukotrienes and other mediators of inflammation, cytokine binds free radicals, generated by nonspecific inflammation and tissue damage, due to enteric shell released in therapeutically effective concentrations in the site of inflammation in the terminal section of small intestine and ascending Department of the colon. Contraindications to the use of here reducing to the drug, local intestinal infection (bacterial, fungal, amebic, virus), signs of cirrhosis and portal hypertension.